Hims & Hers Delivers Huge Growth Despite Stock Drop
Feb 24, 2025
Hims & Hers - our best performing pick ever - reported another outstanding quarter and fiscal year. For the year, revenues were up 69%, with Q4 coming in 95% higher than the comparable quarter last year - its fastest growth quarter of the year. The company has a lot of momentum. Monthly revenue per subscriber was up 19% of the year, 38% for the quarter. HIMS ended the year with 2.2 million subscribers, a 45% increase over last year. Yes, I know the stock has plummeted from $70 down to the low $40's, but the $70 number was just market foolishness over GLP hype. The truth is that less than 15% of Hims & Hers business is GLP drugs, and the company grew revenue 43% even taking that out entirely. With my new (and greatly raised) $35 price target, where it trades now is approaching fair value. This is going to be a wild ride, and my plan is to just ride it out. The trajectory should be up - way up - over time. Let your winners ride!
Follow @GreenDotStocks
Information contained on this website represents only the opinions of the author and should not be used as the sole basis for investing decisions. By using this site, you agree to all statements in the Site Policy.
Watch List
| RDDT | 7.71% |
| NTNX | 31.52% |
| CRWD | 63.06% |
| SE | 29.38% |
| SNOW | 7.59% |
| APPF | 4.88% |
| PINS | -23.24% |
vs. Fair Value Estimates
Buy List
| SEMR | -38.26% |
| TSM | -38.57% |
| GOOG | -51.98% |
| NYAX | -58.66% |
| MSFT | -31.00% |
| ODD | -31.84% |
| ASR | -28.02% |
| FLYW | -38.06% |
| HRMY | -54.53% |
| YOU | -35.24% |
| ABNB | -32.20% |
| MELI | -29.43% |
| ADBE | -40.48% |
vs. Fair Value Estimates
Hold List
| VTEX | -18.40% |
| ZETA | -23.56% |
| CELH | 34.60% |
| TOST | 11.93% |
| CPNG | -15.62% |
| HIMS | -16.74% |
| PAYC | -21.31% |
| MNDY | 6.93% |
| GLBE | -22.43% |
| ZS | 27.08% |
| V | -5.03% |
| ADSK | -3.10% |
| NOW | -3.65% |
| FTNT | -5.29% |
| TEAM | -4.39% |
vs. Fair Value Estimates